SEC Form 4 · accession 0001144204-18-054992
Marker Therapeutics, Inc. · MRKR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Loiacono
Officer — Chief Financial Officer
Period of report
Oct 19, 2018
Accepted (ET)
Oct 23, 2018 · 5:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001094038
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $9.18 | Oct 19, 2018 | A | 300,000 | A | — | Oct 19, 2028 | Common Stock | 300,000 | 300,000 | D |
Explanation of responses
- F1Represents options granted under the Company's 2014 Omnibus Stock Ownership Plan, as amended. These shares vest in monthly installments over a four year period upon the continued employment of the Reporting Person by the Company through the vesting dates. The option exercise price is the closing price on the date of the grant, October 19, 2018.